Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay

Timothy J. Abram, Curtis R. Pickering, Alexander K. Lang, Nancy E. Bass, Rameez Raja, Cynthia Meena, Amin M. Alousi, Jeffrey N. Myers, John McDevitt, Ann M. Gillenwater, Nadarajah Vigneswaran

Research output: Contribution to journalArticle

Abstract

Fanconi anemia (FA) is a hereditary genomic instability disorder with a predisposition to leukemia and oral squamous cell carcinomas (OSCCs). Hematopoietic stem cell transplantation (HSCT) facilitates cure of bone marrow failure and leukemia and thus extends life expectancy in FA patients; however, survival of hematologic malignancies increases the risk of OSCC in these patients. We developed a “cytology-on-a-chip” (COC)–based brush biopsy assay for monitoring patients with oral potentially malignant disorders (OPMDs). Using this COC assay, we measured and correlated the cellular morphometry and Minichromosome Maintenance Complex Component 2 (MCM2) expression levels in brush biopsy samples of FA patients’ OPMD with clinical risk indicators such as loss of autofluorescence (LOF), HSCT status, and mutational profiles identified by next-generation sequencing. Statistically significant differences were found in several cytology measurements based on high-risk indicators such as LOF-positive and HSCT-positive status, including greater variation in cell area and chromatin distribution, higher MCM2 expression levels, and greater numbers of white blood cells and cells with enlarged nuclei. Higher OPMD risk scores were associated with differences in the frequency of nuclear aberrations and differed based on LOF and HSCT statuses. We identified mutation of FAT1 gene in five and NOTCH-2 and TP53 genes in two cases of FA patients’ OPMD. The high-risk OPMD of a non-FA patient harbored FAT1, CASP8, and TP63 mutations. Use of COC assay in combination with visualization of LOF holds promise for the early diagnosis of high-risk OPMD. These minimally invasive diagnostic tools are valuable for long-term surveillance of OSCC in FA patients and avoidance of unwarranted scalpel biopsies.

Original languageEnglish (US)
Pages (from-to)477-486
Number of pages10
JournalTranslational Oncology
Volume11
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Fanconi Anemia
Optical Imaging
Cell Biology
Hematopoietic Stem Cell Transplantation
Squamous Cell Carcinoma
Minichromosome Maintenance Complex Component 2
Biopsy
Leukemia
Mutation
Genomic Instability
p53 Genes
Physiologic Monitoring
Hematologic Neoplasms
Life Expectancy
Chromatin
Anemia
Early Diagnosis
Leukocytes
Bone Marrow
Maintenance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay. / Abram, Timothy J.; Pickering, Curtis R.; Lang, Alexander K.; Bass, Nancy E.; Raja, Rameez; Meena, Cynthia; Alousi, Amin M.; Myers, Jeffrey N.; McDevitt, John; Gillenwater, Ann M.; Vigneswaran, Nadarajah.

In: Translational Oncology, Vol. 11, No. 2, 01.04.2018, p. 477-486.

Research output: Contribution to journalArticle

Abram, TJ, Pickering, CR, Lang, AK, Bass, NE, Raja, R, Meena, C, Alousi, AM, Myers, JN, McDevitt, J, Gillenwater, AM & Vigneswaran, N 2018, 'Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay', Translational Oncology, vol. 11, no. 2, pp. 477-486. https://doi.org/10.1016/j.tranon.2018.01.014
Abram, Timothy J. ; Pickering, Curtis R. ; Lang, Alexander K. ; Bass, Nancy E. ; Raja, Rameez ; Meena, Cynthia ; Alousi, Amin M. ; Myers, Jeffrey N. ; McDevitt, John ; Gillenwater, Ann M. ; Vigneswaran, Nadarajah. / Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay. In: Translational Oncology. 2018 ; Vol. 11, No. 2. pp. 477-486.
@article{be48f5fa204d4d2095e8d3ab680387f1,
title = "Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay",
abstract = "Fanconi anemia (FA) is a hereditary genomic instability disorder with a predisposition to leukemia and oral squamous cell carcinomas (OSCCs). Hematopoietic stem cell transplantation (HSCT) facilitates cure of bone marrow failure and leukemia and thus extends life expectancy in FA patients; however, survival of hematologic malignancies increases the risk of OSCC in these patients. We developed a “cytology-on-a-chip” (COC)–based brush biopsy assay for monitoring patients with oral potentially malignant disorders (OPMDs). Using this COC assay, we measured and correlated the cellular morphometry and Minichromosome Maintenance Complex Component 2 (MCM2) expression levels in brush biopsy samples of FA patients’ OPMD with clinical risk indicators such as loss of autofluorescence (LOF), HSCT status, and mutational profiles identified by next-generation sequencing. Statistically significant differences were found in several cytology measurements based on high-risk indicators such as LOF-positive and HSCT-positive status, including greater variation in cell area and chromatin distribution, higher MCM2 expression levels, and greater numbers of white blood cells and cells with enlarged nuclei. Higher OPMD risk scores were associated with differences in the frequency of nuclear aberrations and differed based on LOF and HSCT statuses. We identified mutation of FAT1 gene in five and NOTCH-2 and TP53 genes in two cases of FA patients’ OPMD. The high-risk OPMD of a non-FA patient harbored FAT1, CASP8, and TP63 mutations. Use of COC assay in combination with visualization of LOF holds promise for the early diagnosis of high-risk OPMD. These minimally invasive diagnostic tools are valuable for long-term surveillance of OSCC in FA patients and avoidance of unwarranted scalpel biopsies.",
author = "Abram, {Timothy J.} and Pickering, {Curtis R.} and Lang, {Alexander K.} and Bass, {Nancy E.} and Rameez Raja and Cynthia Meena and Alousi, {Amin M.} and Myers, {Jeffrey N.} and John McDevitt and Gillenwater, {Ann M.} and Nadarajah Vigneswaran",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.tranon.2018.01.014",
language = "English (US)",
volume = "11",
pages = "477--486",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "2",

}

TY - JOUR

T1 - Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay

AU - Abram, Timothy J.

AU - Pickering, Curtis R.

AU - Lang, Alexander K.

AU - Bass, Nancy E.

AU - Raja, Rameez

AU - Meena, Cynthia

AU - Alousi, Amin M.

AU - Myers, Jeffrey N.

AU - McDevitt, John

AU - Gillenwater, Ann M.

AU - Vigneswaran, Nadarajah

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Fanconi anemia (FA) is a hereditary genomic instability disorder with a predisposition to leukemia and oral squamous cell carcinomas (OSCCs). Hematopoietic stem cell transplantation (HSCT) facilitates cure of bone marrow failure and leukemia and thus extends life expectancy in FA patients; however, survival of hematologic malignancies increases the risk of OSCC in these patients. We developed a “cytology-on-a-chip” (COC)–based brush biopsy assay for monitoring patients with oral potentially malignant disorders (OPMDs). Using this COC assay, we measured and correlated the cellular morphometry and Minichromosome Maintenance Complex Component 2 (MCM2) expression levels in brush biopsy samples of FA patients’ OPMD with clinical risk indicators such as loss of autofluorescence (LOF), HSCT status, and mutational profiles identified by next-generation sequencing. Statistically significant differences were found in several cytology measurements based on high-risk indicators such as LOF-positive and HSCT-positive status, including greater variation in cell area and chromatin distribution, higher MCM2 expression levels, and greater numbers of white blood cells and cells with enlarged nuclei. Higher OPMD risk scores were associated with differences in the frequency of nuclear aberrations and differed based on LOF and HSCT statuses. We identified mutation of FAT1 gene in five and NOTCH-2 and TP53 genes in two cases of FA patients’ OPMD. The high-risk OPMD of a non-FA patient harbored FAT1, CASP8, and TP63 mutations. Use of COC assay in combination with visualization of LOF holds promise for the early diagnosis of high-risk OPMD. These minimally invasive diagnostic tools are valuable for long-term surveillance of OSCC in FA patients and avoidance of unwarranted scalpel biopsies.

AB - Fanconi anemia (FA) is a hereditary genomic instability disorder with a predisposition to leukemia and oral squamous cell carcinomas (OSCCs). Hematopoietic stem cell transplantation (HSCT) facilitates cure of bone marrow failure and leukemia and thus extends life expectancy in FA patients; however, survival of hematologic malignancies increases the risk of OSCC in these patients. We developed a “cytology-on-a-chip” (COC)–based brush biopsy assay for monitoring patients with oral potentially malignant disorders (OPMDs). Using this COC assay, we measured and correlated the cellular morphometry and Minichromosome Maintenance Complex Component 2 (MCM2) expression levels in brush biopsy samples of FA patients’ OPMD with clinical risk indicators such as loss of autofluorescence (LOF), HSCT status, and mutational profiles identified by next-generation sequencing. Statistically significant differences were found in several cytology measurements based on high-risk indicators such as LOF-positive and HSCT-positive status, including greater variation in cell area and chromatin distribution, higher MCM2 expression levels, and greater numbers of white blood cells and cells with enlarged nuclei. Higher OPMD risk scores were associated with differences in the frequency of nuclear aberrations and differed based on LOF and HSCT statuses. We identified mutation of FAT1 gene in five and NOTCH-2 and TP53 genes in two cases of FA patients’ OPMD. The high-risk OPMD of a non-FA patient harbored FAT1, CASP8, and TP63 mutations. Use of COC assay in combination with visualization of LOF holds promise for the early diagnosis of high-risk OPMD. These minimally invasive diagnostic tools are valuable for long-term surveillance of OSCC in FA patients and avoidance of unwarranted scalpel biopsies.

UR - http://www.scopus.com/inward/record.url?scp=85044780427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044780427&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2018.01.014

DO - 10.1016/j.tranon.2018.01.014

M3 - Article

VL - 11

SP - 477

EP - 486

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 2

ER -